Evidence map›Paper›PMID 26730945›Full record

ArticlePloS one2016

Novel Promising Estrogenic Receptor Modulators: Cytotoxic and Estrogenic Activity of Benzanilides and Dithiobenzanilides.

Malgorzata Kucinska, Maria-Dolores Giron, Hanna Piotrowska, Natalia Lisiak, Walter H Granig, Francisco-Javier Lopez-Jaramillo, Rafael Salto, Marek Murias, Thomas Erker

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Malgorzata KucinskaDepartment of Toxicology, Poznan University of Medical Sciences, Poznan, Poland.
Maria-Dolores GironDepartment of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, Granada, Spain.
Hanna PiotrowskaDepartment of Toxicology, Poznan University of Medical Sciences, Poznan, Poland.
Natalia LisiakDepartment of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Poznan, Poland.
Walter H GranigDepartment of Medicinal Chemistry, University of Vienna, Vienna, Austria.
Francisco-Javier Lopez-JaramilloDepartment of Organic Chemistry, Institute of Biotechnology, School of Sciences, University of Granada, Granada, Spain.
Rafael SaltoDepartment of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, Granada, Spain.
Marek MuriasDepartment of Toxicology, Poznan University of Medical Sciences, Poznan, Poland.
Thomas ErkerDepartment of Medicinal Chemistry, University of Vienna, Vienna, Austria.
Poznan University of Medical Sciences · PLUniversidad de Granada · ESUniversity of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cytotoxicity of 27 benzanilides and dithiobenzanilides built on a stilbene scaffold and possessing various functional groups in aromatic rings previously described for their spasmolytic properties was assayed on three human cancer cell lines (A549 -lung adenocarcinoma, MCF-7 estrogen dependent breast adenocarcinoma and MDA-MB-231 estrogen independent breast adenocarcinoma) and 2 non-tumorigenic cell lines (CCD39Lu-lung fibroblasts, MCF-12A - breast epithelial). Three compounds (6, 15 and 18) showed selective antiproliferative activity against estrogen dependent MCF-7 cancer cells and their estrogenic activity was further confirmed in MCF-7 transfected with an estrogen receptor reporter plasmid and in HEK239 cells over-expressing the estrogen receptor alpha (ERα). Compound 18 is especially interesting as a potential candidate for therapy since it is highly toxic and selective towards estrogen dependent MCF7 cell lines (IC50 = 5.07 μM versus more than 100 μM for MDA-MB-231) and almost innocuous for normal breast cells (IC50 = 91.46 μM for MCF-12A). Docking studies have shown that compound 18 interacts with the receptor in the same cavity as estradiol although the extra aromatic ring is involved in additional binding interactions with residue W383. The role of W383 and the extended binding mode were confirmed by site-directed mutagenesis.

Indexed as

AnilidesBinding SitesCell LineCell Line, TumorCell ProliferationCell SurvivalEstradiolEstrogen Receptor ModulatorsEstrogensHEK293 CellsHumansMCF-7 CellsModels, MolecularMolecular StructureMutationProtein BindingAnilidesbenzanilideEstradiolEstrogen Receptor ModulatorsEstrogensReceptors, EstrogenThioamides

Identifiers

PMID26730945
PMCPMC4701221
OpenAlexW2224612508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.